Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan, A Retrospective Nhia Database Analysis
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Sunitinib (Primary) ; Pazopanib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 31 Dec 2017.
- 01 Nov 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 21 May 2016 New trial record